Home
Storia in 1 fonti
Pharmalittle: We're reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide “substantial evidence” of efficacy
Raccontata da
statnews.com
Timeline cronologica
- ·
Pharmalittle: We're reading about a U.S. peptide panel's votes, Amgen scuffling with the FDA, and more
An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available
- ·
Pharmalittle: We're reading about FDA views on a Duchenne drug, GSK cost savings, and more
The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims
- ·
FDA expert panel recommends against approval of Capricor’s Duchenne drug
STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.
- ·
Pharmalittle: We're reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide “substantial evidence” of efficacy